Log in

NASDAQ:CPRXCatalyst Pharmaceuticals Stock Price, Forecast & News

$4.41
+0.25 (+6.01 %)
(As of 04/10/2020 06:12 AM ET)
Add
Compare
Today's Range
$4.20
Now: $4.41
$4.43
50-Day Range
$2.61
MA: $3.86
$5.21
52-Week Range
$2.23
Now: $4.41
$7.67
Volume2.27 million shs
Average Volume2.59 million shs
Market Capitalization$456.04 million
P/E Ratio15.21
Dividend YieldN/A
Beta2.06
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More
Catalyst Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$102.31 million
Cash Flow$0.33 per share
Book Value$0.85 per share

Profitability

Net Income$31.88 million

Miscellaneous

Employees51
Market Cap$456.04 million
Next Earnings Date5/11/2020 (Estimated)
OptionableOptionable

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.


Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

How has Catalyst Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CPRX shares have increased by 25.3% and is now trading at $4.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Catalyst Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalyst Pharmaceuticals.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Catalyst Pharmaceuticals.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) issued its quarterly earnings data on Monday, March, 16th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.02. The biopharmaceutical company had revenue of $30.12 million for the quarter, compared to analysts' expectations of $30 million. Catalyst Pharmaceuticals had a return on equity of 45.52% and a net margin of 31.16%. View Catalyst Pharmaceuticals' earnings history.

What price target have analysts set for CPRX?

4 analysts have issued twelve-month target prices for Catalyst Pharmaceuticals' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $9.75 in the next year. This suggests a possible upside of 121.1% from the stock's current price. View analysts' price targets for Catalyst Pharmaceuticals.

What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Catalyst's Firdapse is the company’s first approved product. The drug is the first FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, which was approved in November 2018 and launched in January. The company generated entire first-quarter revenues from Firdapse. Catalyst is also developing Firdapse to treat additional rare neuromuscular diseases. However, all the other candidates in its portfolio are in early stages of development. Thus, the successful development and commercialization of drug candidates are highly crucial for the company. Shares of the company have outperformed the industry year to date. Estimates have remained stable ahead of the Q2 results. The company has a mixed record of earnings surprises in the recent quarters." (7/31/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and PT of $10 per share of CPRX. the FDA approved private company the treatment of LEMS in pts 6 to <17 years of age. This is the first drug approved for pediatric LEMS. However, Catalyst's slighty different salt form of amifampridine, marketed as Firdapse, was the first drug approved for LEMS, but for adults only. We were surprised by this announcement as no clinical studies were conducted in the pediatric population that we are aware of, and the approval relied on studies of the drug in adults with LEMS, including PK data that were then modeled/extrapolated to identify the dosing regimen in pediatric pts."" (5/7/2019)

Has Catalyst Pharmaceuticals been receiving favorable news coverage?

News stories about CPRX stock have trended very negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCatalyst Pharmaceuticals.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a increase in short interest in March. As of March 13th, there was short interest totaling 14,028,300 shares, an increase of 12.9% from the February 27th total of 12,420,000 shares. Based on an average daily trading volume, of 1,915,200 shares, the short-interest ratio is presently 7.3 days. Currently, 14.7% of the shares of the stock are short sold. View Catalyst Pharmaceuticals' Current Options Chain.

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and Cognex (CGNX).

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)
  • Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)
  • Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)
  • Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63)

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $4.41.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $456.04 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe. View additional information about Catalyst Pharmaceuticals.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is http://www.catalystpharma.com/.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel